The pharmaceutical market is squeezed under various policies，The important issue that all pharmaceutical companies are facing are how to maintain growth。What is the specific growth rate of the pharmaceutical market? What is the growth of prescription drugs occupying more than 80%of the Chinese pharmaceutical market?

 

  According to data released by Kuntai Aimei: In 2015, the size of the Chinese prescription drug market in China exceeded 990 billion yuan，Although it still accounts for 85%of the total size of the pharmaceutical market，But the year -on -year growth of sales has dropped to 6%，This growth rate is only half of 2014。Where the hospital is the main sales position of the prescription medicine，77%of the market share，Highlights in the third terminal is the fastest way to grow in 2015，and the minimum share of the retail pharmacy itself，and slow down the growth rate in the past year。

 

 

  ​​If analysis of the treatment category，Chinese patent medicine is the largest category of prescription medicine，Secondly for systemic anti -infective medication。But from the perspective of growth，Driven from the growing chronic illness of slow disease，Drug use of digestive system、The growth rate of the cardiovascular system has a faster growth rate。Under the continuous stake sports betting appMy stake betting appinfluence of restrictions，Specificational anti -infective drugs maintain a lower growth rate。

 

  Specifically，The market change in 2015 is，Chinese patent medicine is not only declining the market share，And the growth rate is in the stage of rapid decline。In addition，For the entire market，The third terminal is growing into the growth force of the prescription drug market，and the previous hospital ending is weak，Retail pharmacy channels, although the expectation value supports the support of prescription outflow policies，But the size is smaller，Not enough to support the development choice of prescription drug companies。

 

  How far does the Chinese medicine prescription medicine grow?

 

 

  2015，Can be called the beginning of the full decline of Chinese medicine。According to IMS data, the market share of Chinese medicine in the overall prescription drug is 21%，growth rate is 4%。and 2013，Chinese patent medicine accounts for 30%of the Chinese pharmaceutical market sales，12.8%sales growth in the overall pharmaceutical market in China，45%from Chinese medicine。

 

  Obviously，Zhongyin Pharmaceutical Prescription Pharmaceuticals Whether it is a share or growth rate，All are presenting a sharp decline。According to statistics from the Health and Family Planning Commission，2015，Hospital's outpatient drug costs increased by 10%year -on -year，4 percentage points from 2014。Under this influence，Chinese patent medicine is relative to intensive、Western medicine with stronger clinical needs，It is often reduced by priority。

 

  From 2015 to the present，Hospital channels have maximized the most affected Chinese medicine prescription medicine to monitor the auxiliary medication catalog。

 

  For many years，A large number of Chinese patent medicine products have long been in the top ten of the Chinese hospital market，Sales are quite large。But starting last year，Inner Mongolia、Yunnan、Anhui、Hebei、Jiangxi、Sichuan、Hubei、Shanxi、Liaoning and other provinces and cities successively introduced the auxiliary medication catalog。For a large number of clinical medication irregularities，Especially stake online sports bettinghigh price、Large dosage、stake betting appUnreasonable medication behavior of auxiliary therapy drugs，Strengthen management，Unreasonable growth of controlling medical expenses。

 

  Where，Danhong injection in the top 20 prescription drug sales in China、Blood Diary Pass Injection、Danshen Chuanlizzine injection, etc., is all included in the key monitoring scope of the auxiliary medication，More Chinese medicine products that have not entered the top ten，It has also been subject to key monitoring，Catalized the auxiliary medication catalog。From the specific data,，thrombosis is still ranked second，Sales in 2015 were 3.866 billion yuan，Shandong Danhong is ranked fourth，Sales are 3.4 billion yuan，One bit increased from 2014，Kang Ai of Changbai Mountain is in the twelfth position，Sales is 2.5 billion yuan，The ranking has not changed。

 

  Auxiliary medication was introduced one after another, it was the end of 2015，So from the perspective of revenue，The impact on it in 2015 is not very prominent。From the perspective of many industries，The impact of the auxiliary medication directory on Chinese medicine is huge, there is no doubt，But it will gradually appear，Execution for at least half a year，Fang can see the effect，So，2016 trend is，Products listed in the auxiliary medication directory will decline more obvious，Among them, traditional Chinese medicine prescription medicine is the target of crowds。

 

  and，It is worth noting that it is，Current medical insurance costs in various places face the bottom，The pressure is quite large，Very much for controlling the cost，The main blow object is the prescription of Chinese medicine。As some experts say，& ldquo; The hospital can completely do not need Chinese medicine & rdquo;，Now the medical insurance is still & ldquo;，Once it arrives & ldquo; can't hold the point of & rdquo;，Chinese patent medicine will inevitably become the main field of cutting off。In addition，Now it is when the new version of the medical insurance directory adjustment，Auxiliary medication becomes considered to be considered，According to the message displayed by the E -drug manager，Although the new Stake Sports Bettingversion of the directory stake online sports bettingadjustment does not follow & ldquo; auxiliary medication & rdquo;，But in consideration。

 

  So，From 2016，and the next day，The market medicine market of Chinese patent medicine will further shrink，Although it can still increase by 4% in 2015，But there may be negative growth in the future，and this is not a positive saying。

 

  The third terminal will be the main force of growth

 

  Export of Chinese medicines in the hospital market，Let Zhong Yaoparel Enterprise change changes in the sales layout，They aimed at the vast third -terminal market。IMS analysis is，With the construction of the grassroots medical system and the advancement of hierarchical diagnosis and treatment，Community Health Center becomes the highest channel for prescription drugs，Among them, 60%of the share and growth are from Chinese medicine and cardiovascular medicine，The growth rate of major categories of major categories is higher than 100 million yuan channels。

 

  According to the type of manufacturer,，Local products contribute about 7 % of the community health center，and this share is still rising。Local products dominate in most categories，The category with the highest sales contribution of multinational products is blood and hematopoietic organs (70%)，Followed by sensor organs (60%)。

 

  The third terminal is a large base，Now it seems to be a relatively chaotic market，Policy transfer is not as good as it among them，The gradual standard of the hospital's side，and the requirements for controlling fees，Implementation of various policies，The growing space is very limited，So，The third terminal that is also very reckless has become the main object of the current main attack of pharmaceutical companies。Squeeze under the hospital，Pharmaceutical companies naturally down，So，In the prescription drug market in 2015，The third terminal has become a fast growth port。

 

  On the other hand，From the long run，Under the background of the reform and class diagnosis and treatment of public hospitals，Although the market growth has not been fully displayed，But China's reform has always been a slow process，Enterprises who are good at seizing opportunities will always take a step ahead，Early layout。

 

  stake betting appFrom the share occupied Stake Sports Bettingby local companies and the situation of multinational enterprises，Third Terminal，The market that has always been difficult for foreign companies to capture，On the one hand, due to cost pressure and ability of grassroots costs，Another party，Under the background of combating commercial bribery at the moment，There are too many problems involved in the third terminal。So，2015 prescription drug growth is a local enterprise faster than multinational enterprises。

 

  Now，China Pharmaceutical Market，Whether it is the hospital or the third terminal，The environment is not ten years ago，Even if the third terminal is now like the hospital for three or five years ago，But the market's play is definitely not the previous play，The challenge to the enterprise is also quite large。but，What you can see is，The third terminal will inevitably become the driving force for the growth of the pharmaceutical industry in the next round of the pharmaceutical industry。